Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Lallemand

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|January 26, 2010
Adjuvant activity of cytokinesMichael G Tovey, Christophe Lallemand
Therapeutic Advances in Drug Safety|August 2, 2014
Immunogenicity and other problems associated with the use of biopharmaceuticalsMichael G Tovey, Christophe Lallemand
Bioanalysis|September 28, 2012
Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticalsMichael G Tovey, Christophe Lallemand
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Safety, Tolerability, and Immunogenicity of InterferonsMichael G Tovey, Christophe Lallemand
Biological Chemistry|October 28, 2008
Adjuvant activity of type I interferonsMichael G Tovey, Christophe Lallemand, George Thyphronitis
Expert Review of Clinical Pharmacology|November 26, 2011
Overcoming immunogenicity associated with the use of biopharmaceuticalsMichael G Tovey, Julie Legrand, Christophe Lallemand
Vaccine|July 11, 2006
Adjuvant activity of interferon alpha: mechanism(s) of actionMichael G Tovey, Christophe Lallemand, Jean-Francois Meritet, et al.
Journal of Immunological Methods|March 20, 2010
One-step assay for quantification of neutralizing antibodies to biopharmaceuticalsChristophe Lallemand, Jean-Francois Meritet, Brigitte Blanchard, et al.
EMBO Reports|January 31, 2002
GAAP-1: a transcriptional activator of p53 and IRF-1 possesses pro-apoptotic activityChristophe Lallemand, Marta Palmieri, Brigitte Blanchard, et al.
Experimental Gerontology|August 14, 2003
Association of increased autophagic inclusions labeled for beta-galactosidase with fibroblastic agingLuc-Marie Gerland, Simone Peyrol, Christophe Lallemand, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|January 26, 2010
Adjuvant activity of cytokinesMichael G Tovey, Christophe Lallemand
Therapeutic Advances in Drug Safety|August 2, 2014
Immunogenicity and other problems associated with the use of biopharmaceuticalsMichael G Tovey, Christophe Lallemand
Bioanalysis|September 28, 2012
Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticalsMichael G Tovey, Christophe Lallemand
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Safety, Tolerability, and Immunogenicity of InterferonsMichael G Tovey, Christophe Lallemand
Biological Chemistry|October 28, 2008
Adjuvant activity of type I interferonsMichael G Tovey, Christophe Lallemand, George Thyphronitis
Expert Review of Clinical Pharmacology|November 26, 2011
Overcoming immunogenicity associated with the use of biopharmaceuticalsMichael G Tovey, Julie Legrand, Christophe Lallemand
Vaccine|July 11, 2006
Adjuvant activity of interferon alpha: mechanism(s) of actionMichael G Tovey, Christophe Lallemand, Jean-Francois Meritet, et al.
Journal of Immunological Methods|March 20, 2010
One-step assay for quantification of neutralizing antibodies to biopharmaceuticalsChristophe Lallemand, Jean-Francois Meritet, Brigitte Blanchard, et al.
EMBO Reports|January 31, 2002
GAAP-1: a transcriptional activator of p53 and IRF-1 possesses pro-apoptotic activityChristophe Lallemand, Marta Palmieri, Brigitte Blanchard, et al.
Experimental Gerontology|August 14, 2003
Association of increased autophagic inclusions labeled for beta-galactosidase with fibroblastic agingLuc-Marie Gerland, Simone Peyrol, Christophe Lallemand, et al.
Pageof 2